To read Monnier’s original commentary, click here
I have read with interest the response of Edelman et al. to my commentary.1 On the basis of their own observations,2 and of a recent paper published by Marrero et al.3, Edelman et al. conclude that the clinical benefits of pramlintide treatments (loss of body weight [−1.3 kg], improvement in postprandial glucose excursions, and reduction in insulin doses [−12%]) largely overcome the adverse events (gastrointestinal effects and increased rates of hypoglycemic episodes) that occurred in a minority of patients, especially in those who experienced more nausea. Considering the results of Marrero et al.3 who reported that the pramlintide-treated patients were globally satisfied by the adjunction of pramlintide to insulin, I can admit that the relatively low rate of adverse events does not impair the acceptability of the pramlintide treatment. However, I would remain much more skeptical about the long-term efficacy of pramlintide. In both the studies of Edelman et al.2 and Marrero et al.,3 the patients exhibited mean HbA1c levels slightly above 8.0% at baseline and mean reductions in HbA1c levels of 0.4–0.5%, which were approximately similar in the pramlintide and the placebo-treated groups. These results seem to indicate that pramlintide treatments fail to achieve the recommended HbA1c targets in most patients with HbA1c levels above 8%. Furthermore, these observations raise the question whether pramlintide treatments can specifically prevent the risk for developing diabetic complications. If we hypothesize that such an effect exists, it could be due to the ability of pramlintide to reduce the postprandial glucose excursions and as a consequence the acute glucose fluctuations. According to these remarks, and from a general point of view, further long-term studies comparing the effects of pramlintide and placebo treatments should be conducted in insulin-treated patients with HbA1c levels in the range of 7–8%. Such studies might answer the important question whether pramlintide is helpful as an adjunct to insulin in order to maintain glucose control as near to normal as safely possible4 and to reduce the risk for developing diabetic complications.
References
Monnier L (2007) Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab 3: 332–333
Edelman S et al. (2006) A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 29: 2189–2195
Marrero DG et al. (2007) Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care 30: 210–216
American Diabetes Association (2007) Standards of medical care in diabetes–2007. Diabetes Care 30 (suppl 1): S4–S41
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Monnier, L. Author’s response to “Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?”. Nat Rev Endocrinol 3, E2 (2007). https://doi.org/10.1038/ncpendmet0507
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0507